Effect of calcium dobesilate on retrobulbar blood flow and choroidal thickness in patients with non-proliferative diabetic retinopathy.
Calcium dobesilate
Choroidal thickness
Doxium
Non-proliferative diabetic retinopathy
Retrobulbar blood flow
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
07
2020
accepted:
07
06
2021
pubmed:
3
8
2021
medline:
22
9
2021
entrez:
2
8
2021
Statut:
ppublish
Résumé
Diabetic retinopathy is one of the most common causes of blindness in work-aging adults and develops in one third of diabetic patients. Calcium dobesilate (CaD) treatment have protective effects on blood retinal barrier (BRB) and anti-oxidant as well as anti-inflammatory properties. To assess effects of CaD administration on retrobulbar blood flow and choroidal thickness in patients with diabetic retinopathy. In this quasi-experimental study, diabetic patients with diabetic retinopathy (DR) were recruited from Shahid Motahari and Poostchi ophthalmology clinic affiliated to Shiraz University of Medical Sciences. Patients were treated with CaD, 1 gr per day for seven days. Before and after CaD administration, retrobulbar blood flow and subfoveal choroidal thickness were assessed. Retrobulbar blood flow were evaluated by measuring peak systolic velocity (PSV), end diastolic velocity (EDV) and resistive index (RI) of ophthalmic artery (OA), central retinal artery (CRA) and short ciliary artery (SCA). In this study, 26 DR patients with a mean age of 56.15 ± 8.93 years and mean diabetes mellitus duration of 15.04 ± 7.64 years were enrolled. Subfoveal choroidal thickness was significantly increased from 316.08 ± 61.69 to 327.81 ± 58.03 after CaD treatment (P value < 0.001). PSV of CRA and EDV of all arteries were significantly increased after CaD administration. In addition, RI of all arteries was significantly reduced after CaD treatment (P < 0.001). CaD treatment may improve the ophthalmic blood flow and increase the subfoveal choroidal thickness in DR patients. These results may be suggestive of protective effects of CaD on endothelium function as well as microvascular circulation.
Identifiants
pubmed: 34338961
doi: 10.1007/s10792-021-01914-x
pii: 10.1007/s10792-021-01914-x
doi:
Substances chimiques
Calcium Dobesilate
5921X1560Q
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3479-3486Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Abadia B, Bartol-Puyal FA, Calvo P, Verdes G, Isanta C, Pablo LE (2019) Mapping choroidal thickness in patients with type 2 diabetes. Can J Ophthalmol. https://doi.org/10.1016/j.jcjo.2019.06.009
doi: 10.1016/j.jcjo.2019.06.009
pubmed: 31712028
Abadia B, Sunen I, Calvo P, Bartol F, Verdes G, Ferreras A (2018) Choroidal thickness measured using swept-source optical coherence tomography is reduced in patients with type 2 diabetes. PLoS ONE 13(2):e0191977. https://doi.org/10.1371/journal.pone.0191977
doi: 10.1371/journal.pone.0191977
pubmed: 29394291
pmcid: 5796707
Al-Kharashi AS (2018) Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy. Saudi J Ophthalmol 32(4):318–323. https://doi.org/10.1016/j.sjopt.2018.05.002
doi: 10.1016/j.sjopt.2018.05.002
pubmed: 30581303
pmcid: 6300752
Benarroch IS, Brodsky M, Rubinstein A, Viggiano C, Salama EA (1985) Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res 17(3):131–138. https://doi.org/10.1159/000265364
doi: 10.1159/000265364
pubmed: 4011126
Cai J, Boulton M (2002) The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (Lond) 16(3):242–260. https://doi.org/10.1038/sj.eye.6700133
doi: 10.1038/sj.eye.6700133
Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376(9735):124–136. https://doi.org/10.1016/s0140-6736(09)62124-3
doi: 10.1016/s0140-6736(09)62124-3
pubmed: 20580421
Cui Y, Xu X, Bi H, Zhu Q, Wu J, Xia X et al (2006) Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res 83(4):807–816. https://doi.org/10.1016/j.exer.2006.03.024
doi: 10.1016/j.exer.2006.03.024
pubmed: 16750827
Daubresse JC, Meunier R, Dumont P (1977) A controlled clinical trial of calcium dobesylate in the treatment of diabetic retinopathy. Diabete Metab 3(1):27–30
pubmed: 323086
Esmaeelpour M, Brunner S, Ansari-Shahrezaei S, Nemetz S, Povazay B, Kajic V et al (2012) Choroidal thinning in diabetes type 1 detected by 3-dimensional 1060 nm optical coherence tomography. Invest Ophthalmol Vis Sci 53(11):6803–6809. https://doi.org/10.1167/iovs.12-10314
doi: 10.1167/iovs.12-10314
pubmed: 22952126
Feghhi M, Farrahi F, Abbaspour M, Takhtaeian A (2014) Effect of adding oral calcium dobesilate to laser photocoagulation on the macular thickness in patients with diabetic macular edema: a randomized clinical trial. Adv Pharm Bull 4(4):375–378. https://doi.org/10.5681/apb.2014.055
doi: 10.5681/apb.2014.055
pubmed: 25436194
pmcid: 4137428
Garay RP, Hannaert P, Chiavaroli C (2005) Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 4(4):221–232
doi: 10.2165/00024677-200504040-00003
Haas A, Trummer G, Eckhardt M, Schmut O, Uyguner I, Pfeiffer KP (1995) Effect of calcium dobesilate on progression of diabetic retinopathy. Klin Monbl Augenheilkd 207(1):17–21. https://doi.org/10.1055/s-2008-1035343
doi: 10.1055/s-2008-1035343
pubmed: 7564132
Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW (2009) Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 373(9672):1364–1371. https://doi.org/10.1016/s0140-6736(09)60218-x
doi: 10.1016/s0140-6736(09)60218-x
pubmed: 19376452
Horvath H, Kovacs I, Sandor GL, Czako C, Mallar K, Recsan Z et al (2018) Choroidal thickness changes in non-treated eyes of patients with diabetes: swept-source optical coherence tomography study. Acta Diabetol 55(9):927–934. https://doi.org/10.1007/s00592-018-1169-0
doi: 10.1007/s00592-018-1169-0
pubmed: 29876669
Javadzadeh A, Ghorbanihaghjo A, Adl FH, Andalib D, Khojasteh-Jafari H, Ghabili K (2013) Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis 19:62–68
pubmed: 23335852
pmcid: 3548576
Kern TS (2007) Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007:95103. https://doi.org/10.1155/2007/95103
doi: 10.1155/2007/95103
pubmed: 18274606
pmcid: 2216058
Krasnicki P, Mariak Z, Ustymowicz A, Proniewska-Skretek E (2006) Assessment of blood flow in the ocular circulation in type 2 diabetes patients with Color Doppler imaging. Klin Oczna 108(7–9):294–298
pubmed: 17290827
Laurenti O, Vingolo EM, Desideri GB, Ferri C, Bellini C, Cassone-Faldetta M et al (1997) Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage. Exp Clin Endocrinol Diabetes 105(Suppl 2):40–42. https://doi.org/10.1055/s-0029-1211795
doi: 10.1055/s-0029-1211795
pubmed: 9288543
Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J et al (2010) Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 59(10):2637–2645
doi: 10.2337/db09-1421
Leite EB, Mota MC, de Abreu JR, Cunha-Vaz JG (1990) Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol 14(2):81–88. https://doi.org/10.1007/bf00154206
doi: 10.1007/bf00154206
pubmed: 2187006
Luo XX, Duan JG, Liao PZ, Wu L, Yu YG, Qiu B et al (2009) Effect of qiming granule on retinal blood circulation of diabetic retinopathy: a multicenter clinical trial. Chin J Integr Med 15(5):384–388. https://doi.org/10.1007/s11655-009-0384-5
doi: 10.1007/s11655-009-0384-5
pubmed: 19802544
Pearson AR, Keightley SJ, Casswell AG (1998) How good are we at assessing driving visual fields in diabetics? Eye (Lond) 12(Pt 6):938–942. https://doi.org/10.1038/eye.1998.243
doi: 10.1038/eye.1998.243
Rayess N, Rahimy E, Ying GS, Bagheri N, Ho AC, Regillo CD et al (2015) Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol 159(1):85–91.e81–83. https://doi.org/10.1016/j.ajo.2014.09.033
doi: 10.1016/j.ajo.2014.09.033
Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG (2006) Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol 244(12):1591–1600. https://doi.org/10.1007/s00417-006-0318-2
doi: 10.1007/s00417-006-0318-2
pubmed: 16763797
Rota R, Chiavaroli C, Garay RP, Hannaert P (2004) Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 495(2–3):217–224. https://doi.org/10.1016/j.ejphar.2004.05.019
doi: 10.1016/j.ejphar.2004.05.019
pubmed: 15249173
Simo R, Ballarini S, Cunha-Vaz J, Ji L, Haller H, Zimmet P, Wong TY (2015) Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review. Curr Med Chem 22(21):2580–2589. https://doi.org/10.2174/0929867322666150520095923
doi: 10.2174/0929867322666150520095923
pubmed: 25989912
pmcid: 4997935
Simo R, Hernandez C (2015) Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res 48:160–180. https://doi.org/10.1016/j.preteyeres.2015.04.003
doi: 10.1016/j.preteyeres.2015.04.003
pubmed: 25936649
Sudhalkar A, Chhablani JK, Venkata A, Raman R, Rao PS, Jonnadula GB (2015) Choroidal thickness in diabetic patients of Indian ethnicity. Indian J Ophthalmol 63(12):912–916. https://doi.org/10.4103/0301-4738.176024
doi: 10.4103/0301-4738.176024
pubmed: 26862096
pmcid: 4784079
Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P et al (2001) Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol 428(2):277–286. https://doi.org/10.1016/s0014-2999(01)01196-7
doi: 10.1016/s0014-2999(01)01196-7
pubmed: 11675046
Wilkinson C, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110(9):1677–1682
doi: 10.1016/S0161-6420(03)00475-5
Wong TY, Cheung CM, Larsen M, Sharma S, Simo R (2016) Diabetic retinopathy. Nat Rev Dis Primers 2:16012. https://doi.org/10.1038/nrdp.2016.12
doi: 10.1038/nrdp.2016.12
pubmed: 27159554
Zhong H, Guo L (1997) The plasma levels of endothelin in diabetic retinopathy and their changes after treatment with doxium. Hunan Yi Ke Da Xue Xue Bao 22(1):56–58
pubmed: 9868029